Shukla Sath 4
4 · Spero Therapeutics, Inc. · Filed Aug 29, 2024
Insider Transaction Report
Form 4
Shukla Sath
CEO & President
Transactions
- Sale
Common Stock
2024-08-27$1.35/sh−2,757$3,722→ 1,140,809 total
Footnotes (1)
- [F1]The reported transaction is a sale of common stock effected to cover tax withholding obligations pursuant to a "sell to cover" provision included in each RSU Agreement in connection with the vesting of RSUs that were granted to the Reporting Person on August 26, 2021.